

GSK appoints Kevin Sin as SVP, Global Research Head

20 April 2018 | News

Kevin will join GSK in July 2018 from Genentech, where he is currently Vice President and Global Head of Oncology Business Development.



GlaxoSmithKline (GSK) has announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development. In this position, Kevin will play a critical role in strengthening GSK's pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients.

Kevin will join GSK in July 2018 from Genentech, where he is currently Vice President and Global Head of Oncology Business Development, responsible for partnering, acquisition and licensing activities for novel oncology therapeutics.

He has worked within the pharmaceutical and life sciences industry for over 20 years in roles spanning business development, legal and research. Prior to joining Genentech in 2006, Kevin was an attorney advising private and public life sciences companies on business development and strategic partnering transactions. He began his career as a scientist.

Kevin holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a post graduate degree (Juris Doctor) from the University of San Francisco School of Law.